RNA-based Therapeutics Market Size, Share & Trends Analysis Report By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, Other Therapeutics), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Others), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Nanoparticles, Viral Vectors, Naked RNA), By End User, By Region and By Segment Forecasts, 2025-2034
RNA-based Therapeutics Market Segmentation:
RNA-based Therapeutics Market by Product-
- Vaccines
- Drugs
RNA-based Therapeutics Market Based on Type-
- mRNA Therapeutics
- RNA Interference (RNAi) Therapeutics
- Antisense Oligonucleotide (ASO) Therapeutics
- RNA Aptamer
- Other Therapeutics
RNA-based Therapeutics Market Based on Indication-
- Infectious Diseases
- Rare Genetic Diseases/Hereditary Diseases
- Oncology
- Ophthalmology
- Hematological Disorders
- Acute Hepatic Porphyria (AHP)
- Others
RNA-based Therapeutics Market Based on End-User-
- Hospitals and Clinics
- Research Settings
RNA-based Therapeutics Market By Delivery Mechanism-
- Lipid Nanoparticles (LNPs)
- Polymer-Based Nanoparticles
- Viral Vectors
- Naked RNA
RNA-based Therapeutics Market Based on Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RNA-based Therapeutics Market Snapshot
Chapter 4. Global RNA-based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global RNA-based Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on RNA-BASED THERAPEUTICS MARKET Industry Trends
Chapter 5. RNA-based Therapeutics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Vaccines
5.2.2. Drugs
Chapter 6. RNA-based Therapeutics Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Infectious Diseases
6.2.2. Rare Genetic Diseases/Hereditary Diseases
6.2.3. Oncology
6.2.4. Ophthalmology
6.2.5. Hematological Disorders
6.2.6. Acute Hepatic Porphyria (AHP)
6.2.7. Others
Chapter 7. RNA-based Therapeutics Market Segmentation 3: By Type, Estimates & Trend Analysis
7.1. Market Share by Type, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Type:
7.2.1. mRNA Therapeutics
7.2.2. RNA Interference (RNAi) Therapeutics
7.2.3. Antisense Oligonucleotide (ASO) Therapeutics
7.2.4. RNA Aptamer
7.2.5. Other Therapeutics
Chapter 8. RNA-based Therapeutics Market Segmentation 4: By Delivery Mechanism, Estimates & Trend Analysis
8.1. Market Share by Delivery Mechanism, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Mechanism:
8.2.1. Lipid Nanoparticles (LNPs)
8.2.2. Polymer-Based Nanoparticles
8.2.3. Viral Vectors
8.2.4. Naked RNA
Chapter 9. RNA-based Therapeutics Market Segmentation 5: By End-User, Estimates & Trend Analysis
9.1. Market Share by End-User, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User:
9.2.1. Hospitals and Clinics
9.2.2. Research Settings
Chapter 10. RNA-based Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global RNA-based Therapeutics Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.2.3. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.2.4. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.2.5. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.2.6. North America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.3. Europe
10.3.1. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.3.3. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.3.4. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.3.5. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.3.6. Europe RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.4.3. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.4.4. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Type, 2021-2034
10.4.5. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Delivery Mechanism, 2021-2034
10.4.6. Asia Pacific RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.5. Latin America
10.5.1. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.5.3. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.5.4. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.5.5. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.5.6. Latin America RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
10.6.3. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
10.6.4. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
10.6.5. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Delivery Mechanism, 2021-2034
10.6.6. Middle East & Africa RNA-based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Biogen Inc.
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Type
11.2.1.3. Financial PerProductance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. TME Pharma
11.2.3. IVERIC bio (Astellas Pharma)
11.2.4. Olix Pharmaceuticals
11.2.5. GlaxoSmithKline Plc
11.2.6. Sanofi S.A
11.2.7. Alnylam Pharmaceuticals
11.2.8. Ionis Pharmaceuticals
11.2.9. Benitec Biopharma Ltd
11.2.10. Acuitas Therapeutics
11.2.11. Arbutus Biopharma
11.2.12. Silence Therapeutics Plc
11.2.13. Enzon Pharmaceuticals Inc
11.2.14. Bio-Path Holdings Inc.
11.2.15. Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.)
11.2.16. Percheron Therapeutics Limited
11.2.17. Gene Signal
11.2.18. Gradalis
11.2.19. iCo Therapeutics
11.2.20. Aptose Biosciences
11.2.21. Viridian Therapeutics, Inc.
11.2.22. Mirna Therapeutics Inc (Synlogic, Inc.)
11.2.23. Adhera Therapeutics
11.2.24. Achieve Life Sciences, Inc.
11.2.25. Syntara Limited
11.2.26. Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.)
11.2.27. Regulus Therapeutics (Novartis)
11.2.28. Phio Pharmaceuticals Corp.
11.2.29. Santaris Pharma A/S (Roche)
11.2.30. Sarepta Therapeutics
11.2.31. Sirnaomics Inc.
11.2.32. Dicerna Pharmaceuticals (Novo Nordisk)
11.2.33. Others
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
RNA-based Therapeutics Market is valued at USD 12.4 Billion in 2024 and is predicted to reach USD 22.6 Billion by the year 2034
Global RNA-based Therapeutics Market is expected to grow at a 6.5% CAGR during the forecast period for 2025-2034.
RNA-based Therapeutics Market Companies are Biogen Inc., TME Pharma, IVERIC bio (Astellas Pharma), Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Percheron Therapeutics Limited, Gene Signal, Gradalis, iCo Therapeutics, Aptose Biosciences, Viridian Therapeutics, Inc., Mirna Therapeutics Inc (Synlogic, Inc.), Adhera Therapeutics, Achieve Life Sciences, Inc., Syntara Limited, Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.), Regulus Therapeutics (Novartis), Phio Pharmaceuticals Corp., Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., Dicerna Pharmaceuticals (Novo Nordisk) and Others
Product, Type, Indication, End-User and Delivery Mechanism are the key segments of the RNA-based Therapeutics Market.
North America region is leading the RNA-based Therapeutics Market.